Vincerx Pharma Inc (VINC) USD0.0001
Sell:$1.22Buy:$1.27
$0.01
(0.80%)
- This stock can be held in a
Stocks and Shares ISA$0.01
(0.80%)$0.01
(0.80%)Company Information
About this company
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Key people
Key facts
- EPIC-
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS92731L3042
- Market cap$2.84m
- Employees42
- Shares in issue2.24m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.